Lords Mark Industries Limited has completed Phase I of its expansion at the Silvassa facility nearly three months ahead of its original December 2026 timeline.

The company announced the milestone on September 16, 2026, stating that the newly expanded production line is scheduled to commence commercial operations from October 11, 2026.

Portfolio Expansion

The expansion significantly broadens the company’s surgical and orthopaedic product portfolio. The total number of stock keeping units (SKUs) has increased from 36 to 54, marking an addition of 18 new products.

Regulatory Status

The existing portfolio of 36 surgical and orthopaedic products already holds US FDA approval. The newly introduced 18 SKUs are currently progressing through the US FDA approval process. The company anticipates receiving clearance for these new products before December 2026.

Strategic Outlook

This strategic move reinforces the company’s manufacturing capabilities and broadens its market reach across domestic and international healthcare ecosystems. The expansion supports the long-term vision of becoming a recognized global player in the medical devices industry.

Lords Mark Industries Limited provided financial guidance for FY27 during an investor summit on September 10, 2026, projecting consolidated revenue of ₹1,550 crore. The management expects EBITDA margins to reach 20.8% and PAT margins of 12.8% for the fiscal year. This outlook reflects a strategic shift toward higher-margin medical technology products alongside its established renewable energy business.

Financial Outlook and Segment Mix

The company anticipates that the MedTech and IVD segments will contribute approximately ₹825 crore to the total revenue, representing more than half of the top line. Management indicated that MedTech is expected to take the lead over the renewable energy business in terms of revenue contribution in the coming years.

The margin profile varies significantly across business verticals. The IVD and MedTech segment is projected to deliver an EBITDA margin of 23.65% and a PAT margin of 15.46%. In contrast, the renewable energy division is expected to report lower margins, with EBITDA at 17.41% and PAT at 11.8%.

MedTech Growth Drivers

Lords Mark highlighted several new product launches and partnerships driving the MedTech vertical. The company acquired Renalytics in 2025, which manufactures India's first AI-powered dialysis machine. Management confirmed a confirmed order book of over 500 dialysis machines and plans to operate 50 dialysis centers by March 2027, up from 15 currently operational centers.

Other key developments include:

• Launch of the proprietary sickle cell screening device, aligned with the National Sickle Cell Elimination Mission.
• Exclusive distribution rights for Dozee, a contactless remote patient monitoring system.
• Recent US export orders worth close to $1 million for surgical products.
• Plans to launch two oncology cancer care centers in Vapi and Solapur by June 2027.

Renewable Energy and Order Book

The renewable energy division continues to rely on long-term government contracts. Management disclosed a confirmed order book worth ₹2,000 crore extending through 2030, with expectations of an additional ₹1,000 crore from new contracts. The company remains a key partner for Philips in lighting design, contributing to 26% of Indian railway lighting projects.

What the Numbers Show

The projected revenue mix indicates a significant structural shift in the company's earnings quality. With MedTech contributing roughly 53% of the guided revenue but commanding nearly 6 percentage points higher EBITDA margins than the renewable energy segment, the weighted average profitability is set to expand. This divergence suggests that the growth trajectory in FY27 will be driven less by volume in low-margin infrastructure projects and more by high-margin consumable sales in diagnostics and devices.

Balance Sheet and Liquidity

Addressing investor concerns regarding working capital, management clarified that consolidated receivables stood at ₹450 crore against a full-year revenue of ₹1,290 crore. The company stated these levels are within historical controls. Regarding cash flows, management noted that while FY26 cash flow was negative due to capex on new product streams, operating cash flow is expected to turn positive in FY27 or by Q2FY28 at the latest.

The company also outlined plans to meet the Minimum Public Shareholding (MPS) requirement through a dilution of 4-5%, comprising a 3% Offer for Sale (OFS) where promoters infuse funds back into the company, and a 2% issuance of preference or equity shares.